Increasing evidence suggests that both CD4+ and CD8+ T cells play a critical role in cancer immunosurveillance and anti-tumor immunity, and manipulation of these immune cells to recognize and eradicate tumor cells is a promising strategy for treating patients with invasive and metastatic cancers. This evidence concerns the gene CD4 and neoplasm.